Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis

Background: The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC. Methods: We conducted a t...

Full description

Bibliographic Details
Main Authors: Moritz Müller, Florian Posch, Dominik Kiem, Dominik Barth, Lena Horvath, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Richard Greil, Philipp J. Jost, Andreas Seeber, Arno Amann, Konstantin Schlick, Armin Gerger, Jakob M. Riedl
Format: Article
Language:English
Published: SAGE Publishing 2021-09-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211039930

Internet

https://doi.org/10.1177/17588359211039930

Similar Items